摘要
目的探讨阿托伐他汀对子宫肌瘤发展变化的影响。方法选取2012年6月~2014年6月就诊于温州医科大学附属第二医院的子宫肌瘤患者142例。选择子宫肌瘤合并高脂血症口服20mg/d阿托伐他汀患者为用药组,选择子宫肌瘤合并高脂血症未服用他汀类药物患者为高血脂组,选择同期子宫肌瘤且血脂正常未服用他汀类药物患者为正常血脂组。观察比较2年内各组患者子宫肌瘤体积变化情况。结果高血脂组、正常血脂组1年后及2年后肌瘤体积呈增大趋势,且与同组肌瘤原始体积比较差异均有统计学意义(P<0.05)。用药组1年后及2年后肌瘤体积与原始肌瘤体积比较差异均无统计学意义(P>0.05)。高血脂组1年时肌瘤体积变化明显大于用药组1年时肌瘤体积变化(P<0.05)。高血脂组、正常血脂组2年时肌瘤体积变化均大于用药组2年时肌瘤体积变化,差异有统计学意义(P<0.05)。结论育龄期女性子宫肌瘤总体呈增大趋势,治疗高脂血症的阿托伐他汀能明显抑制子宫肌瘤的发展。
Objective To investigate the clinical effect of atorvastatin on the growth of uterine fibroids. Methods One hundred and forty-two patients with uterine fibroids diagnosed at the Second Affiliated Hospital of Wenzhou Medical University from June 2012 to June 2014 were selected. Patients with uterine fibroids and hyperlipidemia were treated with orally 20mg atorvastatin every day, named Atorvastatin group. Patients with uterine fibroids and hyperlipidemia were not treated with statins, named Hyperlipidemia group. Normolipidemic patients with uterine fibroids were not treated with statins, named Control group. The volume of all patients＇ uterine fibroids was evaluated before, after 1 year and after 2 years of treatments. Results When compared to the primary volume, the volume of uterine fibroids in Hyperlipidemia group and Control group was significantly increased after 1 year and 2 years （P〈0.05）, while no significant difference was seen in Atorvastatin group （P〉0.05）. The fibroids volume increased more in the Hyperlipidemia group than Atorvastatin group after 1 year （P〈0.05）. Comparing with the volume change after 2 years in Atorvastatin group, the volume increase in Hyperlipidemia group and Control group was significantly higher （P〈0.05）. Conclusion The volume of uterine fibroids tends to increase at the reproductive women. Atorvastatin can significantly inhibit the growth of uterine fibroids.
作者
盛波
沈昭君
涂权梅
朱雪琼
Sheng Bo;Shen Zhaojun;Tu Quanmei(Department of Obstetrics and Gynecology,The Second Affiliated Hospital of Wenzhou Medical University,Zhejiang 325027,China)
出处
《医学研究杂志》
2018年第8期150-153,共4页
Journal of Medical Research
基金
温州市公益性社会发展(医疗卫生)科技计划项目(2015Y0551)
